Combining the cannabinoid cannabinol (CBN) with the breast cancer drug exemestane may significantly improve treatment ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for ...

Balancing estrogen isn’t just about cutting soy—it’s about strategic, science-backed foods that go beyond the basics ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The report provides product descriptions, patent details, and ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the ...

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers recurring. The decision by the National Institute for Health and Care ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...